These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 435685)

  • 1. Shape change of blood platelets--a model for cerebral 5-hydroxytryptamine receptors?
    Graf M; Pletscher A
    Br J Pharmacol; 1979 Apr; 65(4):601-8. PubMed ID: 435685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
    Michal F; Motamed M
    Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine (5-HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [125I]-iodoLSD binding at 5-HT2 receptors.
    Brazell C; McClue SJ; Preston GC; King B; Stahl SM
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):17-24. PubMed ID: 1772986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of D-LSD with blood platelets of rabbits: shape change and specific binding.
    Laubscher A; Pletscher A; Noll H
    J Pharmacol Exp Ther; 1981 Feb; 216(2):385-9. PubMed ID: 6109775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of [3H]lysergic acid diethylamide binding to a 5-hydroxytryptamine receptor on human platelet membranes.
    Geaney DP; Schächter M; Elliot JM; Grahame-Smith DG
    Eur J Pharmacol; 1984 Jan; 97(1-2):87-93. PubMed ID: 6698111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid intracellular release of calcium in human platelets by stimulation of 5-HT2-receptors.
    Erne P; Pletscher A
    Br J Pharmacol; 1985 Feb; 84(2):545-9. PubMed ID: 3156650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood platelets as models for neurons: uses and limitations.
    Pletscher A; Laubscher A
    J Neural Transm Suppl; 1980; (16):7-16. PubMed ID: 6933224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-hydroxytryptamine receptor of blood platelets.
    Pletscher A; Affolter H
    J Neural Transm; 1983; 57(4):233-42. PubMed ID: 6655466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new antagonist of the 5-hydroxytryptamine receptor of blood platelets.
    Laubscher A; Pletscher A; Mester L; Mester M
    Arzneimittelforschung; 1982; 32(6):686-8. PubMed ID: 7202374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture.
    Dumuis A; Sebben M; Bockaert J
    Mol Pharmacol; 1988 Feb; 33(2):178-86. PubMed ID: 2828913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets.
    Affolter H; Burkard WP; Pletscher A
    Eur J Pharmacol; 1985 Jan; 108(2):157-62. PubMed ID: 3156755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.
    Born GV; Juengjaroen K; Michal F
    Br J Pharmacol; 1972 Jan; 44(1):117-39. PubMed ID: 5015032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood platelets as models for central 5-hydroxytryptaminergic neurons.
    Pletscher A; Laubscher A; Graf M; Saner A
    Ann Biol Clin (Paris); 1979; 37(1):35-9. PubMed ID: 443611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.
    Dumuis A; Bouhelal R; Sebben M; Cory R; Bockaert J
    Mol Pharmacol; 1988 Dec; 34(6):880-7. PubMed ID: 2849052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
    Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
    J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saturable uptake of [3H]-tryptamine in rabbit platelets is inhibited by 5-hydroxytryptamine uptake blockers.
    Segonzac A; Tateishi T; Langer SZ
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Nov; 328(1):33-7. PubMed ID: 6514017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-hydroxytryptamine and platelet aggregation.
    De Clerck FF; Herman AG
    Fed Proc; 1983 Feb; 42(2):228-32. PubMed ID: 6822293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shape change reaction of platelets in protein-free medium: ultramorphology.
    Graf M; Richards JG; Colombo V; Pletscher A
    Experientia; 1979 Jun; 35(6):840-2. PubMed ID: 467611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.